

FACT SHEET:

Women & Infants Microbiome

The Microbiome & Probiotics R&D and Business Collaboration Forum has 4 conference tracks covering topics across research, funding, commercialization and regulation of various applications, including the Gut, Skin, Early Life & Infant Microbiome, Women's Health, Diet and Personalised Nutrition.

You can customize your agenda from any of the conference tracks, roundtable sessions, [poster presentations](#) and networking forums.

To help you navigate the whole, larger agenda, here are the highlights relating to conditions Women & Infants Microbiome:

DAY ONE

10.40 Poster Presentations | Refreshments & Networking

Session 2	Vaginal Microbiota Management and Impact on Women's Health Liisa Lehtoranta, R&D Manager, Nutrition & Biosciences, DuPont
WOMENS HEALTH	Beyond the bacteriome – vaginal and gut mycobiome and inflammatory balance Duccio Cavalieri, Professor of Microbiology, University of Florence
	Vaginal Microbiome Marie Drago, Founder, Gallinée

13.35 Lunch

Session 3	POSTER COMPETITION WINNERS TALK If interested in submitting a poster and/or applying to present a poster on the programme, please CLICK HERE and apply before the deadline 27th April 2020
WOMENS HEALTH	Vaginal Microbiome Hana Janebdar, Founder and CEO, Juno Bio
	The rationale of probiotics in urogenital female healthcare Franco Vicariotto, Specialist Obstetrics and Gynecology, Senior consultant of San PIO X Hospital Milan, Italy

16.10 Poster Presentations | Refreshments & Networking

Session 4	Rachel Teitelbaum, CEO, Hervana Bio (<i>Reserved</i>) Or
WOMENS HEALTH	Roundtable 3 Human milk probiotics in infant microbiota development Monika Schaubek, Nutritional Scientist Team Science, Department Research and Development, HiPP

DAY TWO

Day two will focus on the Gut-Brain Axis, Diagnostics & Microbiome Biobanks and the Skin Microbiome.

Paulo Refinetti, CEO and Founder of, REM Analytics
Probiotic "Drug-discovery" finding a treatment for vulvovaginal candidiasis
Recurrent Vulvovaginal candidiasis (VVC) is a chronic condition affecting between 5 and 10% of women worldwide. It is caused by the formation of biofilms in the vagina by Candida yeasts. Candida are normal symbiont of the human, and it is not its presence, but its behaviour that causes the disease. Using a new tool for microbiome profile, 90 women, for a total of 480 vaginal microbiome sample have been analysed. The samples contain both women affected by VVC and others that are not. From the analysis results it is possible to identify signatures of VVC in the microbiome. These signatures represent a first step towards identifying targets for treatment

Roundtable Discussions

Two roundtables will explore themes related to the infant microbiome. Roundtables are informal, small-group interactive discussions on key topics in the field. The topics to select from, relating to this subject are:

Roundtable #2: The microbiome, probiotics and infant health
Host: Yemi Adesokan, Co-Founder and CSO, GNUbiotics
Roundtable #4: Infant gut microbiome in term and preterm infants
Host: David Kyle, Chairman and CSO, Evolve Biosystems

DAY THREE

8.20	Refreshments
Session 1	The role of the infant gut microbiota in shaping immune and allergy development during childhood Maria Jenmalm, Professor of Experimental Allergology, Linkoping University
EARLY LIFE AND INFANT	Setting the stage for long and healthy life Ger Rijkers, Professor in Biomedical and Life Sciences, University of Roosevelt, The Netherlands
10.40	Poster Presentations Refreshments & Networking
Session 2	Establishment of the gut microbiome in early life: A target for promoting later health Miguel Gueimonde Fernández, Research Scientist, IPLA-CSIC
EARLY LIFE AND INFANT	The Natural Symbiosis Between B. infantis and HMO Provides Colonization Protection for the Early Infant Gut: David Kyle, Chairman and CSO, Evolve Biosystems
	HMOs: Functionality through Diversity, Natures Way Yemi Adesokan, Co-Founder and CSO, GNUbiotics
13.05	Lunch
Session 3	The breast milk microbiome: Community dynamics and cultivability of keystone microbial species to improve preterm health. Lydia Mapstone, CEO and co-founder, BoobyBiome
EARLY LIFE AND INFANT	The microbiome of the female reproductive tract, pregnancy and women's health Gregory Buck, Professor, Microbiology & Immunology & Computer Science, Virginia Commonwealth University)
	Early Life and Infant Francesco Savino, Department of Paediatrics, Universitaria Città della Salute e della Scienza di Torino Italy (<i>Reserved</i>)
	Conference close

Also on the agenda are:

Business Practices

- Investment & funding
- Collaborations between academia, SMEs and pharma
- Translational research policies
- Standardisation
- Intellectually property protection
-

Tools and Technologies for Microbiome Discovery

- High-throughput culturing and other culturing methodologies
- Advances in sequencing method development
- Multi-omics approaches; genomics, metagenomics, metabolomics
- Bioinformatic tools; data analysis and integration
- Systems biology and modelling microbial communities

...and much more.